Nabriva Therapeutics (Nabriva Therapeutics) ROCE % : 0.00% (As of Jun. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Nabriva Therapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Nabriva Therapeutics's annualized ROCE % for the quarter that ended in Jun. 2023 was 0.00%.

Nabriva Therapeutics ROCE % Historical Data

The historical data trend for Nabriva Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nabriva Therapeutics ROCE % Chart

Nabriva Therapeutics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

ROCE %

Get a 7-Day Free Trial

-130.88

-93.47

-115.34

-97.60

-175.10

Nabriva Therapeutics Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
ROCE %	Get a 7-Day Free Trial															-97.79	-139.61	-580.75	-13,609.60	-

Nabriva Therapeutics ROCE % Calculation

Nabriva Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2022 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	-54.919	/	( ( (80.909 - 22.34)	+	(31.765 - 27.605) )	/ 2 )
	=	-54.919	/	( (58.569	+	4.16)	/ 2 )
	=	-54.919	/	31.3645
	=	-175.10 %

Nabriva Therapeutics's ROCE % of for the quarter that ended in Jun. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2023 )		(Q: Mar. 2023 )		(Q: Jun. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2023 )		(Q: Mar. 2023 )		(Q: Jun. 2023 )
	=	-48.096	/	( ( (24.338 - 27.998)	+	(10.578 - 26.203) )	/ 2 )
	=	-48.096	/	( ( -3.66	+	-15.625 )	/ 2 )
	=	-48.096	/	-9.6425
	=	0 %

(1) Note: The EBIT data used here is four times the quarterly (Jun. 2023) EBIT data.

Nabriva Therapeutics (OTCPK:NBRVF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Nabriva Therapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of Nabriva Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Nabriva Therapeutics (Nabriva Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nabriva Therapeutics PLC (OTCPK:NBRVF) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Alexandra House, Office 225/227, The Sweepstakes, Dublin, IRL, 4

Website

https://www.nabriva.com

Nabriva Therapeutics PLC is a clinical stage biopharmaceutical company. Nabriva is engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The company has developed a product candidate, XENLETA, a semi-synthetic pleuromutilin antibiotic that is the first in its class for oral and IV administration in humans. XENLETA is designed to inhibit the synthesis of a specific protein on the bacterial ribosome. It operates in one reportable segment, which comprises the research and development of novel anti-infective agents to treat serious infections. The firm has commercial rights to two approved products, SIVEXTRO and XENLETA, as well as one development product candidate, CONTEPO.

Executives

Hogan H Michael Iii	officer: Chief Executive Officer	C/O 3D SYSTEMS, 26081 AVENUE HALL, VALENCIA CA 91355
David Maggio	officer: Chief Financial Officer	15950 N. DALLAS PARKWAY, SUITE 600, DALLAS TX 75248
Mark Corrigan	director
Broom Colin Md	officer: Chief Executive Officer	119 FRINGETREE DRIVE, WEST CHESTER PA 19380
Stephen W Webster	director	C/O OPTIMER PHARMACEUTICALS, INC, 101 HUDSON STREET, SAN DIEGO CA 07302
Daniel D Burgess	director	C/O HOLLIS-EDEN PHARMACEUTICALS, 4435 EASTGATE MALL STE.400, SAN DIEGO CA 92121
Carrie L. Bourdow	officer: Director	C/O TREVENA, INC., 1018 WEST 8TH AVENUE, SUITE A, KING OF PRUSSIA PA 19406
Rowland Charles A Jr	director	3338 LANCASHIRE RD, FURLONG PA 18925
Theodore R Schroeder	officer: Chief Executive Officer	12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
J. Christopher Naftzger	officer: General Counsel and Corp Sec	633 LOWTHER ROAD, LEWISBERRY PA 17339
Christine J. Guico-pabia	officer: Chief Medical Officer	C/O NABRIVA THERAPEUTICS PLC, 414 COMMERCE DRIVE, SUITE 120, FORT WASHINGTON PA 19034
Lisa Dalton	director	3737 MARKET STREET, SUITE 1300, PHILADELPHIA PA 19104
Daniel Dolan	officer: Chief Financial Officer	C/O NABRIVA THERAPEUTICS PLC, 1000 CONTINENTAL DRIVE, SUITE 600, KING OF PRUSSIA PA 19406
Francesco Maria Lavino	officer: Chief Commercial Officer	1000 CONTINENTAL DRIVE, SUITE 600, KING OF PRUSSIA PA 19406
Robert Crotty	officer: General Counsel & Corp Sec.	1301 2ND AVE, SEATTLE WA 98101